Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

Cancer Cell

Volumn 28, Issue 2, 2015, Pages 225-239

  Ronca, Roberto ^a   Giacomini, Arianna ^a   Di Salle, Emanuela ^a   Coltrini, Daniela ^a   Pagano, Katiuscia ^b   Ragona, Laura ^b   Matarazzo, Sara ^a   Rezzola, Sara ^a   Maiolo, Daniele ^a   Torrella, Rubben ^c   Moroni, Elisabetta ^c   Mazzieri, Roberta ^d   Escobar, Giulia ^e,f   Mor, Marco ^g   Colombo, Giorgio ^c   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Istituto Per Lo Studio Delle Macromolecole Milan   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; NSC 12; NSC 21; PENTAPEPTIDE; PENTRAXIN 3; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; MOLECULAR LIBRARY; SERUM AMYLOID P;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CELL PROLIFERATION; CHICK EMBRYO; COMPLEX FORMATION; CONTROLLED STUDY; DRUG IDENTIFICATION; EMBRYO; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MELANOMA B16; METASTASIS INHIBITION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETICULOSARCOMA; SURFACE PLASMON RESONANCE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR RING; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PHARMACOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ANIMALS; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM AMYLOID P-COMPONENT; SMALL MOLECULE LIBRARIES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939444543     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.07.002     Document Type: Article

References (42)

1. Accardi L., Paolini F., Mandarino A., Percario Z., Di Bonito P., Di Carlo V., Affabris E., Giorgi C., Amici C., Venuti A. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int. J. Cancer 2014, 134:2742-2747.
2. Bai A., Meetze K., Vo N.Y., Kollipara S., Mazsa E.K., Winston W.M., Weiler S., Poling L.L., Chen T., Ismail N.S., et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010, 70:7630-7639.
3. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
4. Bonavita E., Gentile S., Rubino M., Maina V., Papait R., Kunderfranco P., Greco C., Feruglio F., Molgora M., Laface I., et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015, 160:700-714.
5. Bono F., De Smet F., Herbert C., De Bock K., Georgiadou M., Fons P., Tjwa M., Alcouffe C., Ny A., Bianciotto M., et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013, 23:477-488.
6. Brooks A.N., Kilgour E., Smith P.D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin. Cancer Res. 2012, 18:1855-1862.
7. Brown A.P., Courtney C.L., King L.M., Groom S.C., Graziano M.J. Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. Toxicol. Pathol. 2005, 33:449-455.
8. Camozzi M., Rusnati M., Bugatti A., Bottazzi B., Mantovani A., Bastone A., Inforzato A., Vincenti S., Bracci L., Mastroianni D., Presta M. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J. Biol. Chem. 2006, 281:22605-22613.
9. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
10. Colombo G., Margosio B., Ragona L., Neves M., Bonifacio S., Annis D.S., Stravalaci M., Tomaselli S., Giavazzi R., Rusnati M., et al. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J. Biol. Chem. 2010, 285:8733-8742.
11. Daigo K., Mantovani A., Bottazzi B. The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunol. Lett. 2014, 161:38-43.
12. De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007, 28:519-524.
13. Dieci M.V., Arnedos M., Andre F., Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013, 3:264-279.
14. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 2005, 23:337-366.
15. Giacomini A., Matarazzo S., Pagano K., Ragona L., Rezzola S., Corsini M., Di Salle E., Presta M., Ronca R. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget 2015, 6:13790-13802.
16. Han X., Xiao Z., Quarles L.D. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J. Biol. Chem. 2015, 290:10447-10459.
17. Harding T.C., Long L., Palencia S., Zhang H., Sadra A., Hestir K., Patil N., Levin A., Hsu A.W., Charych D., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 2013, 5:178ra39.
18. Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320.
19. Herbert C., Schieborr U., Saxena K., Juraszek J., De Smet F., Alcouffe C., Bianciotto M., Saladino G., Sibrac D., Kudlinzki D., et al. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 2013, 23:489-501.
20. Ho H.K., Yeo A.H., Kang T.S., Chua B.T. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov. Today 2014, 19:51-62.
21. Inforzato A., Baldock C., Jowitt T.A., Holmes D.F., Lindstedt R., Marcellini M., Rivieccio V., Briggs D.C., Kadler K.E., Verdoliva A., et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J. Biol. Chem. 2010, 285:17681-17692.
22. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004, 20:563-569.
23. Leali D., Bianchi R., Bugatti A., Nicoli S., Mitola S., Ragona L., Tomaselli S., Gallo G., Catello S., Rivieccio V., et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J. Cell. Mol. Med. 2010, 14:2109-2121.
24. Leali D., Alessi P., Coltrini D., Ronca R., Corsini M., Nardo G., Indraccolo S., Presta M. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol. Cancer Ther. 2011, 10:1600-1610.
25. Leali D., Inforzato A., Ronca R., Bianchi R., Belleri M., Coltrini D., Di Salle E., Sironi M., Norata G.D., Bottazzi B., et al. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:696-703.
26. Lieu C., Heymach J., Overman M., Tran H., Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 2011, 17:6130-6139.
27. Maiolo D., Mitola S., Leali D., Oliviero G., Ravelli C., Bugatti A., Depero L.E., Presta M., Bergese P. Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation. J. Am. Chem. Soc. 2012, 134:14573-14579.
28. Martin A., David V., Quarles L.D. Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 2012, 92:131-155.
29. Pagano K., Torella R., Foglieni C., Bugatti A., Tomaselli S., Zetta L., Presta M., Rusnati M., Taraboletti G., Colombo G., Ragona L. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS ONE 2012, 7:e36990.
30. Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999, 98:641-650.
31. Polnaszek N., Kwabi-Addo B., Peterson L.E., Ozen M., Greenberg N.M., Ortega S., Basilico C., Ittmann M. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003, 63:5754-5760.
32. Presta M., Oreste P., Zoppetti G., Belleri M., Tanghetti E., Leali D., Urbinati C., Bugatti A., Ronca R., Nicoli S., et al. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler. Thromb. Vasc. Biol. 2005, 25:71-76.
33. Presta M., Camozzi M., Salvatori G., Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J. Cell. Mol. Med. 2007, 11:723-738.
34. Richard C., Liuzzo J.P., Moscatelli D. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J. Biol. Chem. 1995, 270:24188-24196.
35. Ronca R., Alessi P., Coltrini D., Di Salle E., Giacomini A., Leali D., Corsini M., Belleri M., Tobia C., Garlanda C., et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J. Pathol. 2013, 230:228-238.
36. Ronca R., Di Salle E., Giacomini A., Leali D., Alessi P., Coltrini D., Ravelli C., Matarazzo S., Ribatti D., Vermi W., Presta M. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol. Cancer Ther. 2013, 12:2760-2771.
37. Ronca R., Giacomini A., Rusnati M., Presta M. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin. Ther. Targets 2015, 1-17.
38. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. USA 2009, 106:6742-6747.
39. Sun H.D., Malabunga M., Tonra J.R., DiRenzo R., Carrick F.E., Zheng H., Berthoud H.R., McGuinness O.P., Shen J., Bohlen P., et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E964-E976.
40. Talmadge J.E., Hart I.R. Inhibited growth of a reticulum cell sarcoma (M5076) induced in vitro and in vivo by macrophage-activating agents. Cancer Res. 1984, 44:2446-2451.
41. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
42. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 2006, 281:15694-15700.